Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma.

Objectives: Mitotane is the reference drug for the adrenocortical carcinoma treatment; its pharmacological activity seems to depend on drug transformation in two active metabolites: o,p'-DDE (dichlorodiphenylethene) and o,p'-DDA (dichlorodiphenylacetate). Mitotane and metabolites are lipophilic agents; thus, they tend to accumulate into adipose tissues (white and brown), which change their prevalence seasonally. Aim of the work was to evaluate mitotane and metabolites plasma levels variation over the year, in adrenocortical cancer patients treated with Lysodren for at least 6 months.

Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma.

Context: In 2007, a retrospective case-control study provided evidence that adjuvant mitotane prolongs recurrence-free survival (RFS) in patients with radically resected adrenocortical carcinoma (ACC).

Objective And Design: We aimed to confirm the prognostic role of adjuvant mitotane in the same series after 9 additional years of follow-up.

Setting, Patients, And Interventions: One hundred sixty-two ACC patients who did not recur or die after a landmark period of 3 months were considered.

Does nephrectomy during radical adrenalectomy for stage II adrenocortical cancer affect patient outcome?

Purpose: To evaluate if including nephrectomy in the standard surgical approach to stage II adrenocortical cancer (i.e., adrenalectomy) might modify oncologic outcome of patients.

Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection.

Background: Recurrence of adrenocortical carcinoma (ACC) even after complete (R0) resection occurs frequently.

Objective: The aim of this study was to identify markers with prognostic value for patients in this clinical setting.

Design, Setting, And Participants: From the German ACC registry, 319 patients with the European Network for the Study of Adrenal Tumors stage I-III were identified.

MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations.

Several microRNAs (miRNAs) were shown to be deregulated in adrenocortical carcinoma (ACC) as compared with adenoma, but a detailed assessment of their expression in its histologic variants and correlation with clinicopathologic characteristics has not been performed, so far. Our aim was to assess the expression of 5 selected miRNAs (IGF2 gene-related miR-483-3p and 5p and hypoxia-induced miR-210, miR-195, and miR-1974) in a series of 51 ACCs (35 classical, 6 myxoid, and 10 oncocytic) as compared with clinical and pathologic features and immunohistochemical expression of prognostic markers, including steroidogenic factor 1, p53, β-catenin, and glucose transporter 1. Oncocytic carcinomas had a reduced expression of miR-483-3p (P = .